Clinical trial · no report yet · Phase 3
PROOF 302
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
- NCT04197986 ↗
- Terminated
- QED Therapeutics, a BridgeBio company
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 20 | |
| YouTube | 6 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Upper Tract Urothelial Carcinomas; Urothelial Bladder Cancer
- Interventions
- Infigratinib; Placebo
- Arms
- Infigratinib 125 mg · Experimental
- Placebo · Placebo comparator
- Enrollment
- 39
- Primary outcomes
- Centrally Determined Disease-free Survival (DFS)
- Sponsor
- QED Therapeutics, a BridgeBio company with Helsinn Healthcare SA
- Start
- Mar 11, 2020
- Primary completion
- Feb 28, 2023
- Results posted
- Yes
- Registry record
- NCT04197986 · updated Mar 13, 2024
Publications
linked from the registry- Szymaniak J, Porten SP. Which Biomarkers are Useful in the Management of Muscle-invasive Bladder Cancer in 2022? Eur Urol Focus. 2022 Jul;8(4):901-903. doi: 10.1016/j.euf.2022.08.009. Epub 2022 Sep 2. PubMed 36058810
- Pal SK, Somford DM, Grivas P, Sridhar SS, Gupta S, Bellmunt J, Sonpavde G, Fleming MT, Lerner SP, Loriot Y, Hoffman-Censits J, Valderrama BP, Andresen C, Schnabel MJ, Cole S, Daneshmand S. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul;18(21):2599-2614. doi: 10.2217/fon-2021-1629. Epub 2022 May 24. PubMed 35608106